Patient-Reported Symptom Relief Following Medical Cannabis Consumption

Stith, Sarah S.; Vigil, Jacob M.; Brockelman, Franco; Keeling, Keenan; Hall, Branden

doi:10.3389/fphar.2018.00916

Cited by 35 publications

(49 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patterns of use are related to subjective effects to cannabis (Daniulaityte et al 2018;Ware et al 2005). Frequency of use, route of administration, and type of cannabinoid used all impact the effects to cannabis (Stith et al 2019;Sexton et al 2016;Stith et al 2018). A comprehensive study of medical cannabis patients found that the primary route of administration was inhalation (84%); oral administration was only 8, and 0.6% used topicals (Peretti-Watel et al 2003b).…”

Section: Introductionmentioning

confidence: 99%

Age related differences in cannabis use and subjective effects in a large population-based survey of adult athletes

Zeiger¹,

Silvers

Fleegler³

et al. 2019

J Cannabis Res

View full text Add to dashboard Cite

Background: There is a paucity of information regarding cannabis use behaviors in adult community-based athletes as most research in athletes has focused on misuse of cannabis in elite, adolescent, university-based athletes. We aimed to determine whether age related differences exist in patterns of cannabis use and subjective effects to cannabis in adult athletes. Methods:The Athlete PEACE Survey used mainly social media and email blasts to recruit and SurveyGizmo to collect data. Cannabis patterns of use (duration of use, frequency of use, routes of administration, cannabinoid used, concurrent use with exercise), benefits, and adverse effects were reported. Age was reported by decade from 21 to ≥60. Age trends in cannabis use patterns and subjective effects were assessed using linear trend analysis.Results: Of the 1161 participants, 301 (26%) athletes currently used cannabis. Younger athletes compared to older athletes reported significantly more positive and adverse subjective effects to cannabis, used cannabis longer, and used both tetrahydrocannabinol and cannabidiol for medical and recreational purposes. Younger athletes used cannabis concurrently with exercise more often than older athletes and consumed edibles, vaporized, and smoked more than older athletes. Conclusions:We found age-related cannabis patterns of use and subjective effects to cannabis. Concerns about cannabis mis-use and abuse in athletes maybe overstated with the potential benefits (improved sleep, decreased anxiety, less pain) outweighing the adverse effects (increased anxiety, increased appetite, difficulty concentrating).

show abstract

Section: Introductionmentioning

confidence: 99%

Age related differences in cannabis use and subjective effects in a large population-based survey of adult athletes

Zeiger¹,

Silvers

Fleegler³

et al. 2019

J Cannabis Res

View full text Add to dashboard Cite

show abstract

“…Finally, based on a review of the literature, participants were allowed to select up to 9 options of reasons for use: relax/unwind, improve mood, help with pain, help with sleep, help with stress, help with depression, glaucoma, nausea/loss of appetite, and neurologic condition. 14 As many participants selected both adult use (eg, relaxation) and medical (eg, glaucoma) reasons, we separately grouped all men who listed a medical reason (ie, medical use) or did not (ie, adult use) in the primary reason for use variable. The complete distribution of the reason for use is illustrated in Supplemental Table 1 .…”

Section: Methodsmentioning

confidence: 99%

A Survey Exploring the Relationship Between Cannabis Use Characteristics and Sexual Function in Men

Bhambhvani

Kasman

Wilson-King³

2020

Sexual Medicine

View full text Add to dashboard Cite

Introduction Cannabis is the most commonly used drug in the United States; however, the effects of cannabis use on male sexual function are poorly understood. Aim To characterize the contemporary landscape of cannabis use and to assess the associations between male sexual function and the frequency of use, the primary method of consumption, or cannabis chemovar (tetrahydrocannabinol or cannabidiol) among current users. Methods We surveyed adults who visited a single cannabis dispensary for baseline demographic information, medical history, cannabis use habits, and sexual function as assessed by the International Index of Erectile Function (IIEF). An IIEF-5 < 21 was considered erectile dysfunction. Main Outcome Measures The main outcome measure of the study was male sexual function via the IIEF domain scores. Results A total of 325 men completed the survey with a mean age of 46.7 years. 71.1% of the men were Caucasian and 52.6% were married. 13 men (4%) were never users; 29 men (8.9%) used 1–2 times/week; 51 men (15.7%) used 3–5 times/week, and 232 men (71.4%) used 6+ times/week. The average IIEF-5 score was 22.3 with 19.4% of the men having erectile dysfunction. In univariate analysis, men using cannabis more frequently had a higher overall IIEF (65.36 vs 60.52, P = .001), erectile domain (27.32 vs 25.74, P = .03), orgasm domain (9.08 vs 8.12, P < .001), intercourse satisfaction domain (12.42 vs 11.31, P = .006), and overall satisfaction domain (8.11 vs 7.05, P = .002). In multivariable analysis, compared to men who used cannabis 0 times/week, those who used 6 times/week had an increased overall IIEF (69.08 vs 64.64, P -value adjusted = 0.02), intercourse satisfaction domain ( P -value adjusted = 0.04), and overall satisfaction domain ( P -value adjusted = 0.02). The primary method of consumption (eg, smoking, edibles, etc.) and cannabinoid composition (eg, cannabidiol vs tetrahydrocannabinol dominant) were not associated with sexual function. Conclusion We report an association between the increased frequency of cannabis use and increased male sexual function. However, while the increased frequency of use was statistically significant with regard to the IIEF scores, the clinical significance of this is likely low, and selection bias may limit the generalizability of these findings. The method of consumption and cannabis chemovar were not associated with sexual function. Bhambhvani HP, Kasman AM, Wilson-King G, et al. A Survey Exploring the Relationship Between Cannabis Use Characteristics and Sexual Function in Men. J Sex Med 2020;8:436–445.

show abstract

“…Further real-world benefits from CBMPs using patient reports have been reported for Parkinson’s disease ( Balash et al, 2017 ), autism (Bar-Lev Schleider et al, 2019), pain, depression, and anxiety symptoms ( Gulbransen et al, 2020 ). Many patients experience therapeutic satisfaction when using medical cannabis and report improvements in or relief of a range of symptoms ( Gulbransen et al, 2020 ; Stith et al, 2018 ; Sexton et al, 2016 ). Others report using cannabis as an alternative to pharmaceutical prescriptions ( Sith et al, 2018 ) and this can lead to reduced use of opioids for example ( Ueberall et al, 2019 ).…”

Section: Current Evidence Of Medical Valuementioning

confidence: 99%

“…Many patients experience therapeutic satisfaction when using medical cannabis and report improvements in or relief of a range of symptoms ( Gulbransen et al, 2020 ; Stith et al, 2018 ; Sexton et al, 2016 ). Others report using cannabis as an alternative to pharmaceutical prescriptions ( Sith et al, 2018 ) and this can lead to reduced use of opioids for example ( Ueberall et al, 2019 ). Many of these also report that the medical cannabis improves their quality of life ( Bar-Leve Schleider et al, 2019 ; Gulbransen et al, 2020 ; Sith et al, 2018 ).…”

Section: Current Evidence Of Medical Valuementioning

confidence: 99%

Medical cannabis in the UK: From principle to practice

et al. 2020

View full text Add to dashboard Cite

Background: In the UK, medical cannabis was approved in November 2018, leading many patients to believe that the medicine would now be available on the NHS. Yet, to date, there have been only 12 NHS prescriptions and less than 60 prescriptions in total. In marked contrast, a recent patient survey by the Centre for Medical Cannabis (Couch, 2020) found 1.4 m people are using illicit cannabis for medical problems. Aims: Such a mismatch between demand and supply is rare in medicine. This article outlines some of the current controversies about medical cannabis that underpin this disparity, beginning by contrasting current medical evidence from research studies with patient-reported outcomes. Outcomes: Although definite scientific evidence is scarce for most conditions, there is significant patient demand for access to medical cannabis. This disparity poses a challenge for prescribers, and there are many concerns of physicians when deciding if, and how, to prescribe medical cannabis which still need to be addressed. Potential solutions are outlined as to how the medical profession and regulators could respond to the strong demand from patients and families for access to medical cannabis to treat chronic illnesses when there is often a limited scientific evidence base on whether and how to use it in many of these conditions. Conclusions: There is a need to maximise both clinical research and patient benefit, in a safe, cautious and ethical manner, so that those patients for whom cannabis is shown to be effective can access it. We hope our discussion and outlines for future progress offer a contribution to this process.

show abstract

Patient-Reported Symptom Relief Following Medical Cannabis Consumption

Cited by 35 publications

References 39 publications

Age related differences in cannabis use and subjective effects in a large population-based survey of adult athletes

Age related differences in cannabis use and subjective effects in a large population-based survey of adult athletes

A Survey Exploring the Relationship Between Cannabis Use Characteristics and Sexual Function in Men

Medical cannabis in the UK: From principle to practice

Contact Info

Product

Resources

About